Sanofi India Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Sanofi India Ltd with respect to news appearing in The Hindu on March 2, 2017 titled "Sanofi, Boehringer close business swap." Sanofi India Ltd response is enclosed. Better days ahead for Sanofi
The year 2016 was challenging for Sanofi India, the drug maker known for its brands such as Combiflam, vaccines and diabetes portfolio. While the drug price control impacted the company's performance in the early part of CY2016 (follows January-December accounting year), note ban weight on its December quarter numbers. These have led to its stock price remaining under pressure. But, as the impact fades out, analysts expect the company to report a strong rebound in revenue, profitability and thereby stock price, which is why they are now bullish on Sanofi. Post the company reported its December quarter and financial year performance on Monday, analysts have strong buy recommendation on the stock. The expectations stem from the fact that despite pressure due to price control, volume growth in key brands is expected to be strong and will drive overall revenue. Also, launch of new product line extensions and exports of insulin pens will mean further gains. Analysts such as Ranjit Kapadia . Clarification sought from Sanofi India Ltd
The Exchange has sought clarification from Sanofi India Ltd with respect to news article appearing on The Hindu on March 2, 2017 titled "Sanofi, Boehringer close business swap."The reply is awaited. Sanofi, Boehringer Ingelheim close business swap in India
Global healthcare leader Sanofi-Synthelabo (India) and German pharmaceutical firm Boehringer Ingelheim today said they have closed business swap which involves an exchange of over 80 brands between... Updates on Outcome of Board Meeting - Appointment of Statutory Auditors
Sanofi India Ltd has informed BSE that pursuant to the provisions of Section 139 of the Companies Act 2013, as amended, and rules framed thereunder, the Company is required to rotate its Statutory Auditors in the next Annual General Meeting (AGM) of the Company. M/s. SRBC & Co, LLP are the present Statutory Auditors of the Company.The Board of Directors of the Company at its Meeting held on February 27, 2017, subject to the approval of the... Outcome of Board Meeting - Change in Directors
Sanofi India Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on February 27, 2017, took note of resignation of Mr. J. Silvestre and Mr. P. Chocat as Non-Executive Directors of Company from the close of the business hours on February 26, 2017. Consequently, Mr. N. Rajaram and Mr. A. Sood ceased to be Alternate Directors of Mr. J. Silvestre and Mr. P. Chocat respectively. Mr. N. Rajaram and Mr. A. Sood will however... Fixes Book Closure for Dividend & AGM
Sanofi India Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from April 27, 2017 to May 05, 2017 (both days inclusive) for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company to be held on May 05, 2017.The dividend, if approved by the shareholders shall be payable on or after May 11, 2017. Board recommends Dividend
Sanofi India Ltd has informed BSE that the Board Meeting that was scheduled on February 27, 2017. The following items were considered and approved:- Dividend recommendation of Rs. 50 per equity share of Rs. 10 each for the year ended December 31, 2016. Announces Q4 & FY16 results (Standalone) & Auditors Report (Standalone) for the period ended December 31, 2016
Sanofi India Ltd has announced the following results for the quarter & year ended December 31, 2016:The Audited Standalone results for the Quarter ended December 31, 2016The Company has posted a net profit of Rs. 505 million for the quarter ended December 31, 2016 as compared to Rs. 1202 million for the quarter ended December 31, 2015. Total Income has increased from Rs. 5813 million for the quarter ended December 31, 2015 to Rs.... Sanofi & Lonza to jointly set up $ 285-mn biologics production facility
The facility, to be built in Switzerland, is expected to be fully operational by 2020